Quick Answer
Immuneering Corp reported Operating Income of -$59.38 million for fiscal year 2025.
Immuneering Corp Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$59.38M | +7.3% |
| 2024 | -$64.07M | -9.7% |
| 2023 | -$58.41M | -12.9% |
| 2022 | -$51.74M | -52.7% |
| 2021 | -$33.89M | -98.4% |
| 2020 | -$17.08M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$15.38M | -0.7% | -4.2% |
| June 30, 2025 | -$14.76M | +1.0% | +4.7% |
| March 31, 2025 | -$15.48M | -1.0% | -1.4% |
| September 30, 2024 | -$15.27M | -9.7% | -2.4% |
| June 30, 2024 | -$14.91M | -10.4% | +2.7% |
| March 31, 2024 | -$15.33M | -4.4% | -10.0% |
| September 30, 2023 | -$13.93M | -5.6% | -3.1% |
| June 30, 2023 | -$13.50M | -16.0% | +8.0% |
- Immuneering Corp showed an increase of +7.3% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Immuneering Corp’s operating income has declined by 247.6% (from -$17.08 million to -$59.38 million).
- The most recent figure is from Immuneering Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: